2 biotech stocks plummet more than 25% after the FDA rejects their drug applications (GILD, GLPG, BMRN)

2 biotech stocks plummet more than 25% after the FDA rejects their drug applications (GILD, GLPG, BMRN)

  • Three biotechnology stocks plummeted on Wednesday after the FDA issued two separate complete response letters, or CRLs, for two separate drugs.
  • On Tuesday after the market close, Gilead received a CRL for its drug filgotinib, which was devel…

    Read More…

You May Also Like